Explore

Trendline Trendline
Ankyra Therapeutics to Present Novel IL-12 Anchored Immunotherapy at ASCO 2026

Ankyra Therapeutics to Present Novel IL-12 Anchored Immunotherapy at ASCO 2026

Ankyra Therapeutics to Present Novel IL-12 Anchored Immunotherapy at ASCO 2026
Trendline Trendline
Ernexa Therapeutics Advances ERNA-101 Toward Clinical Trials with Key Milestones

Ernexa Therapeutics Advances ERNA-101 Toward Clinical Trials with Key Milestones

Ernexa Therapeutics Advances ERNA-101 Toward Clinical Trials with Key Milestones
Trendline Trendline
Delphia Therapeutics Appoints David P. Kerstein, M.D., as Chief Medical Officer to Advance Cancer Therapies

Delphia Therapeutics Appoints David P. Kerstein, M.D., as Chief Medical Officer to Advance Cancer Therapies

Delphia Therapeutics Appoints David P. Kerstein, M.D., as Chief Medical Officer to Advance Cancer Therapies
Trendline Trendline
Forlong Completes Phase I Trials of FL115 for Advanced Solid Tumors with Promising Results

Forlong Completes Phase I Trials of FL115 for Advanced Solid Tumors with Promising Results

Forlong Completes Phase I Trials of FL115 for Advanced Solid Tumors with Promising Results
Trendline Trendline
Delphia Therapeutics Appoints David P. Kerstein as Chief Medical Officer to Advance Cancer Therapies

Delphia Therapeutics Appoints David P. Kerstein as Chief Medical Officer to Advance Cancer Therapies

Delphia Therapeutics Appoints David P. Kerstein as Chief Medical Officer to Advance Cancer Therapies
Trendline Trendline
Forlong Biotechnology Completes Phase I Trials of FL115 for Advanced Tumors

Forlong Biotechnology Completes Phase I Trials of FL115 for Advanced Tumors

Forlong Biotechnology Completes Phase I Trials of FL115 for Advanced Tumors
Trendline Trendline
Adcendo and MSD Collaborate on Phase Ib Study for Advanced Solid Tumors

Adcendo and MSD Collaborate on Phase Ib Study for Advanced Solid Tumors

Adcendo and MSD Collaborate on Phase Ib Study for Advanced Solid Tumors
Trendline Trendline
Citius Oncology Presents Promising Phase 1 Data on LYMPHIR at ASCO Meeting

Citius Oncology Presents Promising Phase 1 Data on LYMPHIR at ASCO Meeting

Citius Oncology Presents Promising Phase 1 Data on LYMPHIR at ASCO Meeting
Trendline Trendline
Genprex Publishes Positive Biomarker Data for Reqorsa Gene Therapy at ASCO 2026

Genprex Publishes Positive Biomarker Data for Reqorsa Gene Therapy at ASCO 2026

Genprex Publishes Positive Biomarker Data for Reqorsa Gene Therapy at ASCO 2026
Trendline Trendline
Ori Biotech and ImmuXell Partner to Advance Cell Therapy Manufacturing

Ori Biotech and ImmuXell Partner to Advance Cell Therapy Manufacturing

Ori Biotech and ImmuXell Partner to Advance Cell Therapy Manufacturing
Trendline Trendline
Archeus Technologies Begins Phase 1 Trial for Metastatic Cancer Treatment

Archeus Technologies Begins Phase 1 Trial for Metastatic Cancer Treatment

Archeus Technologies Begins Phase 1 Trial for Metastatic Cancer Treatment
Trendline Trendline
Agios Pharmaceuticals Secures EU Approval for PYRUKYND in Thalassaemia Treatment

Agios Pharmaceuticals Secures EU Approval for PYRUKYND in Thalassaemia Treatment

Agios Pharmaceuticals Secures EU Approval for PYRUKYND in Thalassaemia Treatment